Table 2.

Comparison of percentage of respondents who selected each feature by continent.

FeatureEurope, N = 92North America, N = 90Other Continents, N = 50pComparisons Significant on post-hoc Test*
Falling platelet count81.592.2860.1
Hyperferritinemia8891.1620.0002EU vs OC
NA vs OC
Increased liver enzymes69.686.7640.004EU vs NA
NA vs OC
Falling white blood cell count70.782.2660.07
Bone marrow hemophagocytosis79.381.1840.8
Persistent continuous fever ≥ 38° C73.956.7780.01EU vs NA
NA vs OC
Falling erythrocyte sedimentation rate5067.8700.02EU vs NA
Hypofibrinogenemia6364.4520.3
Hypertriglyceridemia69.650520.02EU vs NA
Central nervous system dysfunction53.332.2520.009EU vs NA
NA vs OC
Falling hemoglobin level34.847.8500.1
Prolongation of clotting times20.744.4440.001EU vs NA
EU vs OC
Increased D-dimer18.548.9300.0006EU vs NA
Hemorrhagic manifestations33.722.2420.04NA vs OC
Liver enlargement41.315.6380.0004EU vs NA
NA vs OC
Spleen enlargement27.216.7340.06
Increased lactic dehydrogenase26.117.8100.06
Increased soluble IL-2 receptor α10.9304< 0.0001EU vs NA
NA vs OC
Increased soluble CD1633.321.1100.0008EU vs NA
Generalized lymphadenopathy14.13.3120.03EU vs NA
Decreased albumin8.76.7100.8
Hyponatremia15.22.20< 0.0001EU vs NA
EU vs OC
Arthritis improvement9.82.260.1
Renal failure4.35.680.7
Increased bilirubin4.32.260.5
Jaundice4.31.180.1
Respiratory failure3.32.220.9
Cardiac failure3.3040.2
  • * Pairs of comparisons that were statistically significant after Bonferroni correction for multiple comparisons. EU: Europe; NA: North America; OC: other continents.